Technical Analysis for GH - Guardant Health, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| BB Squeeze Started | Range Contraction | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -2.15% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | -2.15% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -2.15% | |
| Gapped Up | Strength | -2.15% |
| Alert | Time |
|---|---|
| Down 3% | about 7 hours ago |
| Fell Below Previous Day's Low | about 9 hours ago |
| Down 2 % | about 9 hours ago |
| 60 Minute Opening Range Breakdown | about 10 hours ago |
| 10 DMA Resistance | about 10 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 08/01/2024
Guardant Health, Inc. Description
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Biopharmaceutical Cancer Disease Clinical Development Oncology Telehealth Telemedicine Lab Testing Precision Medicine Blood Test Biopsy Healthcare Costs
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 41.06 |
| 52 Week Low | 15.81 |
| Average Volume | 2,235,495 |
| 200-Day Moving Average | 23.95 |
| 50-Day Moving Average | 24.76 |
| 20-Day Moving Average | 29.61 |
| 10-Day Moving Average | 29.37 |
| Average True Range | 1.44 |
| RSI (14) | 51.46 |
| ADX | 38.2 |
| +DI | 23.82 |
| -DI | 17.49 |
| Chandelier Exit (Long, 3 ATRs) | 27.97 |
| Chandelier Exit (Short, 3 ATRs) | 30.39 |
| Upper Bollinger Bands | 31.84 |
| Lower Bollinger Band | 27.37 |
| Percent B (%b) | 0.2 |
| BandWidth | 15.12 |
| MACD Line | 1.03 |
| MACD Signal Line | 1.55 |
| MACD Histogram | -0.519 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 30.53 | ||||
| Resistance 3 (R3) | 30.66 | 30.05 | 30.15 | ||
| Resistance 2 (R2) | 30.05 | 29.47 | 29.98 | 30.02 | |
| Resistance 1 (R1) | 29.15 | 29.11 | 28.85 | 29.02 | 29.90 |
| Pivot Point | 28.54 | 28.54 | 28.38 | 28.47 | 28.54 |
| Support 1 (S1) | 27.64 | 27.96 | 27.34 | 27.51 | 26.62 |
| Support 2 (S2) | 27.03 | 27.60 | 26.96 | 26.50 | |
| Support 3 (S3) | 26.13 | 27.03 | 26.37 | ||
| Support 4 (S4) | 26.00 |
